Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.39 |
| ▸ | KDR | P35968 | 9/20 | 0.36 |
| ▸ | BRAF | P15056 | 6/20 | 0.36 |
| ▸ | AXL | P30530 | 3/20 | 0.36 |
| ▸ | MERTK | Q12866 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GCK | P35557 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4413183 | 0.83 | MEN1 (0.43) | MEN1NPC1TP53TSHRRAB9A | |
| SCHEMBL5359686 | 0.81 | AXL (0.40) | MAPK14KDRBRAFAXLMERTK | |
| SCHEMBL4413188 | 0.76 | KDR (0.39) | MAPK14KDRBRAFGCK | |
| SCHEMBL5358853 | 0.75 | KDR (0.45) | MAPK14KDRBRAFAXLMERTK | |
| SCHEMBL4320095 | 0.74 | KDR (0.44) | KDRBRAF | |
| SCHEMBL4320097 | 0.74 | KDR (0.44) | KDRBRAF | |
| SCHEMBL4328795 | 0.74 | SMN1; SMN2 (0.47) | MEN1KMT2ASMN1; SMN2MAPK14BRAF | |
| SCHEMBL13788545 | 0.73 | MEN1 (0.45) | MEN1TSHRKMT2AMAPK14BRAF | |
| SCHEMBL5371154 | 0.73 | KDR (0.47) | KDRBRAF | |
| SCHEMBL13788616 | 0.72 | MEN1 (0.46) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415382-B2 | Substituted benzazoles and methods of their use as inhibitors of RAF Kinase | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20090035309-A1 | Substituted Benzazoles and Methods of Their Use as Inhibitors of RAF Kinase | NOVARTIS AG | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035309-A1 | Substituted Benzazoles and Methods of Their Use as Inhibitors of RAF Kinase | BRAF, RAF1, ARAF | MEN1 2406/4885NPC1 4051/4885TP53 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.